03/12/2026
Dr. Rutika Mehta spoke with Targeted Oncology about a study looking at using circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing in to help inform prognosis, treatment duration, toxicity, and potential treatment breaks:
ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.